Navigation Links
Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq
Date:1/5/2011

PITTSBURGH, Jan. 5, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has notified The Nasdaq Stock Market, an exchange of the NASDAQ OMX Group Inc. (Nasdaq: NDAQ), that it intends to voluntarily de-list its 1.25% Senior Convertible Notes due 2012 from the Nasdaq Capital Market, on which the notes trade under the ticker symbol "MYLNG," effective as of the open of trading on January 28, 2011. The notes will continue to trade over-the-counter (OTC) with trade data available through the Financial Industry Regulatory Authority's Trade Reporting and Compliance Engine ("TRACE"). Moving the trading of the notes from Nasdaq to the OTC market will bring the company in line with standard capital markets practice and reduce the company's regulatory burden.  

On January 5, 2011, Nasdaq notified the company that the notes did not have the number of market makers required by Nasdaq's continued listing standards. While there are multiple securities firms that regularly trade the notes, these firms do not meet the strict criteria required of a market maker under Nasdaq's listing standards. The de-listing of the notes from Nasdaq does not affect the listing or trading of the company's common stock, ticker symbol "MYL," which will continue uninterrupted on Nasdaq.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylans Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe
2. Mylan Confirms First-to-File Patent Challenge Relating to Orapred ODT®
3. Mylan Receives Approval for Generic Version of Adalat® CC Tablets
4. Mylan Announces the Conversion of its Preferred Stock into Common Stock
5. Mylan Announces Final Conversion Rate for Mandatory Convertible Preferred Stock
6. Third Circuit Denies Mylan Motion for Interim Injunction
7. Mylan Reports Adjusted Diluted EPS of $0.43; Reaffirms 2010 Adjusted Diluted EPS Guidance of $1.55 - $1.65
8. Mylan Declares Quarterly Preferred Stock Dividend
9. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
10. Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar®
11. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create ... it streamlines the reporting process and provides a familiar interface that does not ...
(Date:4/28/2017)... ... ... sleep affects much more than energy – it also has mental and physical benefits. According ... reaction time, which can increase the risk of having a car accident. , This ... NSF to help you sleep better and feel better:, , Turn ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly ... offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and ... These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... exposed to more adverse experiences than children in the general population. That’s because ... abuse, neglect or other family challenges. While no fault of their own, youth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection ... improve drug safety and minimize the cost of development. In this webinar, sponsored ... using cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). ...
Breaking Medicine News(10 mins):